To investigate the effects on airway lumen of talsaclidine in combination with propranolol and of talsaclidine and propranolol given as monosubstances
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Airway resistance (Raw)
Time frame: Up to 8 hours after drug administration
Specific conductance (SGaw)
Time frame: Up to 8 hours after drug administration
Forced expiratory volume in 1 sec (FEV1)
Time frame: Up to 8 hours after drug administration
Number of participants with clinically significant findings in vital signs
Time frame: Up to 8 days after last drug administration
Number of participants with clinically significant findings in laboratory tests
Time frame: Up to 8 days after last drug administration
Number of participants with adverse events
Time frame: Up to 8 days after last drug administration
Cmax (maximum measured concentration of the analyte in plasma)
Time frame: Up to 12 hours after drug administration
tmax (time from dosing to maximum measured concentration of the analyte in plasma)
Time frame: Up to 12 hours after drug administration
AUC (area under the plasma concentration versus time curve)
Time frame: Up to 12 hours after drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.